The company's full-year revenues rose 6 percent and were slightly higher than the consensus Wall Street estimate.
The firm plans to add more oncology tests, NIPTs and newborn screening assays through in-house development and partnerships with third-party assay makers.
The test is for monitoring treatment response in chronic myeloid leukemia and uses a new Droplet Digital PCR instrument.
The kit, which was launched today, leverages real-time RT-PCR technology to detect and quantify hepatitis C virus-specific RNA with genotypes 1 to 6.
The project builds on a collaboration between Bio-Rad and Genetic Analysis using the GA-map clinical test for gut dysbiosis.
The infringement relates to US patents held by the University of Chicago and exclusively licensed to Bio-Rad.
The contract covers Bio-Rad's iQ-Check RT-PCR pathogen detection test kits, which cover pathogens including Salmonella spp. and Listeria monocytogenes.
An increase in sale growth for its life science segment was offset by a flat quarter year over year for its diagnostics sales.
The New York Times Magazine examines gender discrimination at the Salk Institute.
Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.
A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.
In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.